Trial results

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

NCT06662383 on ClinicalTrials.gov · last registry update 2026-07-20

Closed to new participants; the 800 already enrolled are still being followed. Due to report November 2026, alongside 33 other tracked readouts that quarter. Primary outcome, as filed: Percent Change from Baseline in Body Weight. Sponsors move these dates routinely; any movement since this site started watching is listed below. tirzepatide is already approved in the US for obesity, so this is asking a further question rather than establishing the drug works at all.

Status

ACTIVE_NOT_RECRUITING

Phase

P3

Drug

tirzepatide

Zepbound, Mounjaro

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

800

Started

2024-11-01

Primary completion

2026-11 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percent Change from Baseline in Body Weight

Conditions studied

Obesity

Every field above is taken directly from the registry record. See all detected changes across the class, or the tirzepatide page for this molecule’s full trial and approval history.